🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#PRESS Novo Nordisk product achieved 20.7% weight loss in obesity trial, and 18.7% regardless of treatment adherence

#PRESS: Novo Nordisk successfully completes phase 1b/2a trial in people with overweight or obesity

#PRESS Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

#PRESS Once-weekly product is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors

#PRESS Notice for the Annual General Meeting of Novo Nordisk A/S

#PRESS Novo Nordisk product demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in clinical trial

#PRESS The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

#PRESS Product​ shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025

#PRESS Product​ demonstrates superior reduction in cardiovascular events in phase 3b trial at ACC 2025

#PRESS Novo Nordisk announces changes in Executive Management

#PRESS Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025

#PRESS Data presented at the ESPE-ESE 2025 Congress shows that once-weekly growth hormone is non-inferior or superior compared to once-daily standard of care in children with growth failure

#PRESS Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

#PRESS Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk

#PRESS Novo Nordisk to advance subcutaneous and oral product for weight management into phase 3 clinical development

#PRESS: In connection with #ADA2025, Novo Nordisk is sharing new subcutaneous and oral product data in people living with obesity, also published in The Lancet. Read the full press release.

#PRESS: At #ADA2025, Novo Nordisk is presenting new phase 3b results in obesity. Read the full press release

#PRESS: At #ADA2025, Novo Nordisk is sharing the full phase 3 study results in people with overweigh or obesity, and overweight or obesity and type 2 diabetes respectively. Both studies simultaneously published in The New England Journal of Medicine. Read the full press release

#PRESS Prophylaxis treatment with Novo Nordisk molecule shown to be well-tolerated when switching from another product in phase 3 haemophilia A data presented at the ISTH 2025 Congress